Business
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed LONDON and PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data
About this update from Avacta Group Plc
[{"type":"image","alt":"AVACTA GROUP PLC","displaySize":"","headline":null,"caption":"AVACTA GROUP PLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BuJbdPFE1KPW3OqbkUSHWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b","width":300,"height":109}},"lazy":false},{"type":"text","content":"Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025","length":126,"tagName":"p"},{"type":"text","content":"Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed","length":131,"tagName":"p"},{"type":"text","content":"LONDON and PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase 1a part of the study.","length":490,"tagName":"p"},{"type":"text","content":"Faridoxorubicin is the first peptide drug conjugate (PDC) in Avacta’s pipeline. It consists of doxorubicin conjugated with Avacta’s proprietary pre|CISION® peptide and is specifically cleaved (released) by fibroblast activation protein-alpha (FAP), which is over-expressed in the tumor microenvironment, enabling targeted release of the doxorubicin payload.","length":357,"tagName":"p"},{"type":"text","content":"SGC accounts for 6-8% of head and neck cancers, with approximately 2,500 cases diagnosed in the U.S. each year.1 SGC is a disease that does not respond to chemotherapy, has no standard therapy defined in the metastatic setting and a five-year survival rate of approximately 42%2 in advanced stage disease.","length":305,"tagName":"p"},{"type":"text","content":"Avacta’s recent data demonstrate continued robust and meaningful tumor shrinkage in patients with SGCs and a combined disease control rate of 90% across Phas...